menu
    • menu

    Company profile for Kymera Therapeutics

    NEW Drugs in Dev: 9
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Veranova: A CDMO that manages complexity with confidence.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Kymera Therapeutics is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Powered by Pegasus™, a game-changing integrated degradation platform, Kymera is accelerating drug discovery with an un...
    Kymera Therapeutics is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Powered by Pegasus™, a game-changing integrated degradation platform, Kymera is accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Kymera TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    200 Arsenal Yards Blvd., Suite 230 Watertown, MA 02472
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.kymeratx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/kymeratherapeutics/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/KymeraTx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    India Pharma Expo

    Not Confirmed

    envelop Contact Supplier

    India Pharma Expo

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Kymera Therapeutics To Release Q1 2026 Financial Results
    Kymera Therapeutics To Release Q1 2026 Financial Results

    23 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/23/3279714/0/en/kymera-therapeutics-to-report-first-quarter-2026-financial-results-on-april-30-2026.html

    GLOBENEWSWIRE
    23 Apr 2026
    Share Share
    Kymera Pharma's KT-621, Granted FDA Fast Track For Severe Asthma
    Kymera Pharma's KT-621, Granted FDA Fast Track For Severe Asthma

    13 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/13/3272365/0/en/Kymera-Therapeutics-Announces-U-S-FDA-Fast-Track-Designation-for-KT-621-a-First-in-Class-Oral-STAT6-Degrader-for-the-Treatment-of-Moderate-to-Severe-Asthma.html

    GLOBENEWSWIRE
    13 Apr 2026
    Share Share
    Kymera Announces Gilead’ Option Exercise to License KT-200
    Kymera Announces Gilead’ Option Exercise to License KT-200

    10 Apr 2026

    // ENDPOINTS NEWS

    https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-announces-gilead-sciences-option-exercise

    ENDPOINTS NEWS
    10 Apr 2026
    Share Share
    Gilead Pays Kymera $45M For Preclinical Protein Degrader
    Gilead Pays Kymera $45M For Preclinical Protein Degrader

    09 Apr 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/gilead-pays-kymera-45m-glue-preclinical-protein-degrader-burgeoning-oncology-pipeline

    FIERCE BIOTECH
    09 Apr 2026
    Share Share
    Gilead Exercises Kymera's KT-200 Option
    Gilead Exercises Kymera's KT-200 Option

    09 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/09/3270789/0/en/Kymera-Therapeutics-Announces-Gilead-Sciences-Option-Exercise-to-License-KT-200-Oral-CDK2-Molecular-Glue-Degrader-Development-Candidate.html

    GLOBENEWSWIRE
    09 Apr 2026
    Share Share
    Kymera Therapeutics Presents KT-621 Broaden Data at AAD
    Kymera Therapeutics Presents KT-621 Broaden Data at AAD

    28 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/28/3264183/0/en/Kymera-Therapeutics-Presents-KT-621-BroADen-Data-in-Late-Breaking-Research-Session-at-the-American-Academy-of-Dermatology-AAD-Annual-Meeting.html

    GLOBENEWSWIRE
    28 Mar 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search